Courier Therapeutics is a biotechnology startup with a cytotoxic-lymphocyte targeting therapy platform, with a focus on making cancer-immunotherapy safer and more efficacious. Courier's first application of this targeting technology technology, CT101, is a first-in-class IL2R agonist which specifically activates the NK and CD8 T cells against cancer.